Five pharmaceutical manufacturing facilities constructed by companies located in Germany, Switzerland, and the United States have been selected as Category Winners in the fourth annual Facility of the Year Awards program sponsored by ISPE, INTERPHEX, and Pharmaceutical Processing magazine. The companies and respective award categories include: * Boehringer Ingelheim Pharma GmbH & Co.KG, located in Biberach, Germany, winner of the Facility of the Year Award for Facility Integration * Bristol-Myers Squibb, located in New Brunswick, New Jersey, USA, winner of the Facility of the Year Award for Equipment Innovation * IDT Biologika GmbH, located in Dessau-Rosslau, Germany, winner of the Facility of the Year Award for Operational Excellence * Pfizer, located in Illertissen, Germany, winner of the Facility of the Year Award for Process Innovation * F. Hoffmann La Roche AG, located in Basel, Switzerland, winner of the Facility of the Year Award for Project Execution Recent enhancements to this prestigious awards program include naming winners in five specific categories. The Facility of the Year Awards (FOYA) program recognizes state-of-the-art pharmaceutical manufacturing projects that utilize new and innovative technologies to enhance the delivery of a quality project, as well as reduce the cost of producing high-quality medicines. Now in its fourth year, the Awards Program effectively spotlights the accomplishments, shared commitment, and dedication of individuals in companies worldwide to innovate and advance pharmaceutical manufacturing technology for the benefit of all global consumers. “It’s amazing to see the consistency in quality of projects submitted year after year,” said Scott Ludlum, ISPE’s Director of Business Initiatives. “It was not an easy choice for the judges to choose the five winners with so many outstanding projects being submitted. I believe this indicates the commitment of the industry to build truly innovative facilities that reduce costs and improve operational efficiency,” said Ludlum. The Awards Program is truly global, as submissions over the past four years have been received from at least 20 different countries and territories. Each of the submissions was reviewed by an independent, blue-ribbon judging panel of global representatives from the pharmaceutical design, construction, and manufacturing sectors.
